Photocure ASA

Photocure ASA: Change of Board Composition

Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company,

announces changes to the composition of its Board of Directors. Reference is

made to the stock exchange notice on 9 August 2023 and that Jan H. Egberts, M.D.

has decided to step down from his position as Chairperson of the Company's Board

of Directors. Dr. Egberts has now resigned from the Board of Directors of

Photocure ASA.

The current board members of Photocure will constitute the Board of Directors

after Dr. Egberts' resignation until the general meeting elects a new Board of

Directors. Further, the members of the Board of Directors have, after

consultation with the nomination committee, resolved that current board member

Dylan Hallerberg will take the position as interim Chairperson of the Board of

Directors until such election is made.

The nomination committee has initiated a search for a new Chairperson, and it is

expected that the committee will present its recommendations to the annual

general meeting in 2024 at the latest.

For further information, please contact:

Erik Dahl

Chief Financial Officer

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

AI Terminal